Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537935 · ClinicalTrials.gov registry record · Phase 4
Low Dose Naltrexone for Pain in Patients With HIV
A Phase 4 study of Human Immunodeficiency Virus and Chronic Neuropathic Pain, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 3
- Study locations
NCT05537935 is a Phase 4 study of Human Immunodeficiency Virus and Chronic Neuropathic Pain that is actively recruiting participants, run by Emory University. The registered enrollment target is 60 participants, below the 182-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT05537935, a Phase 4 study of Human Immunodeficiency Virus and Chronic Neuropathic Pain, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 3
- Study locations
Study Summary
The increased life expectancy of Patients Living With HIV/AIDS (PLWHA) has increased the need for therapies for chronic conditions, such as chronic pain. Pain in the HIV population is often refractory and ends up being treated with chronic opioids, which are associated with adverse effects, including hyperalgesia, constipation, and risk of overdose. Naltrexone is an opioid antagonist used in the treatment of alcohol and opioid use disorders. Low Dose Naltrexone (LDN), naltrexone at a much lower dose, is thought to be an immune modulator and has been associated with an increased CD4 count in PLWHA. Repurposing this medication is relatively inexpensive and has the potential to expand access to treatment for a painful condition experienced in PLWHA. While there are many case reports on the efficacy of LDN in symptom reduction, there are only a small number of clinical trials that specifically examine pain and symptom relief. This study will include patients who are not completely virologically controlled and will monitor the CD4 counts drawn as a part of routine care. If the CD4 count improves with LDN and with reduced symptoms, this could be a significant improvement in HIV therapy for symptom control. There have been studies showing cytokine reduction in fibromyalgia patients but they did not investigate the correlation with cytokines and pain relief. This study involves repurposing a drug used for substance use disorder to a medication with the potential to treat pain and improve symptoms for PLWHA.
Conditions Studied
Interventions
- DRUG Low Dose Naltrexone
Study Locations (3)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory Midtown Hospital - Atlanta
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-04-28 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05537935
The ClinicalTrials.gov registry entry for NCT05537935 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (67% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Low Dose Naltrexone is the first listed.
NCT05537935 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05537935 about?
NCT05537935 is a clinical study titled "Low Dose Naltrexone for Pain in Patients With HIV". The increased life expectancy of Patients Living With HIV/AIDS (PLWHA) has increased the need for therapies for chronic conditions, such as chronic pain. Pain in the HIV population is often refractory and ends up being treated with chronic opioids, which are associated with adverse effects, includin...
What is the current status of trial NCT05537935?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2023-04-28. Estimated completion is 2026-12.
What conditions does trial NCT05537935 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Chronic Neuropathic Pain.
What interventions are being tested in trial NCT05537935?
The interventions under investigation include: Low Dose Naltrexone (DRUG).
Who is sponsoring clinical trial NCT05537935?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537935 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
Switching Undetectables to Selzentry
COMPLETED · Phase 4
-
HIV Non-Occupational Post-Exposure Prophylaxis
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.